Skip to main content
OpenTrials
Completed

NCT Number: NCT03758651

Williams Syndrome Strength, Hormones, Activity & Adiposity, DNA Programming, Eating Study

Williams syndrome (WS) is a rare microdeletion genetic disorder that has a broad phenotype including many endocrine and metabolic abnormalities. Dr. Pober and colleagues at MGH have reported the following findings in adults with WS: abnormal body composition (excess body fat accumulation with a lipedema phenotype), decreased bone mineral density, abnormal glucose tolerance, and reduced lean mass. Despite the high prevalence and potential effect of metabolic abnormalities on the health of persons with WS, their full phenotypic range, potential causal factors (either genetic and/or hormonal) along with their impact on other aspects of health (such as risk of falls and fractures or interaction with emotional behavioral concerns) remain incompletely characterized. The purpose of the current study in a large cohort of subjects with WS is to: collect further information to characterize the timing of onset and distribution of body fat; better characterize hormonal status of WS subjects; and screen for genetic variation using single-nucleotide-polymorphism (SNP) analysis that could elucidate genetic contributors to the lipedema phenotype as well as the other observed metabolic and bone abnormalities.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

For those participating in-person at Massachusetts General Hospital:

Inclusion criteria

  • Male or Female age 18-70 years old
  • Diagnosis of Williams syndrome (WS), established by experienced clinician, parent report, or confirmed by genetic testing such as FISH (fluorescent in situ hybridization) or chromosomal microarray (WS only)
  • Availability of a parent or guardian to review details of the study with their family member with WS and participate in the consent process (all WS regardless of age)
  • Availability of a parent or guardian to provide selected medical information (WS only)

Exclusion criteria

  • History of weight loss surgery or liposuction
  • Positive urine pregnancy test (females only)
  • Obesity or abnormal fat distribution due to a known secondary cause (except WS) such as Cushing syndrome, HIV-infection, etc.

Treatment and study plan

Primary outcomes

  1. Bone Mineral Density - Lumbar Spine

    Time frame: baseline only

  2. Whole Body DEXA (dual energy x-ray absorptiometry) scan

    Time frame: baseline only

    To assess body proportions of fat, bone, and muscle

Secondary outcomes

  1. Bone Mineral Density - Hip

    Time frame: baseline only

  2. Resting energy expenditure

    Time frame: baseline only

  3. Serum Total Testosterone

    Time frame: baseline only

  4. Serum Estrogen

    Time frame: baseline only

  5. Fasting blood sugar and Oral glucose tolerance test (OGTT)

    Time frame: baseline only

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Collaborators

  • Williams Syndrome Association

Registry information

Official study title

Williams Syndrome SHAAPE STUDY [Strength, Hormones, Activity & Adiposity, DNA Programming, Eating Study]

Acronym: SHAAPE

Important dates

Study start
2018
Primary completion
2022
Study completion
2023
First posted
Nov 29, 2018
Registry last updated
Oct 19, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.